Article
CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
Clinical pharmacokinetics - 1 Aug 2023
van Eerden Ruben A G, IJzerman Nikki S, van Meekeren Milan, Oomen-de Hoop Esther, Guchelaar Niels A D, Visser Andrea M W, Matic Maja, van Schaik Ron H N, de Bruijn Peter, Moes Dirk-Jan A R, Jobse Pieter A, Gelderblom Hans, Huitema Alwin D R, Steeghs Neeltje, Mathijssen Ron H J, Koolen Stijn L W
Abstract excerpt
INTRODUCTION: A genetic variant explaining a part of the exposure of many kinase inhibitors (KIs) is the single nucleotide polymorphism (SNP) CYP3A4*22, resulting in less CYP3A4 enzyme activity. The primary aim of this study was to investigate if the systemic exposure is non-inferior after a dose reduction of KIs metabolized by CYP3A4 in CYP3A4*22 carriers compared to patients without this SNP (i.e., wildtype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.